MRTX — Mirati Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Deals of the day-Mergers and acquisitions
Mirati falls after buyout deal by Bristol-Myers Squibb
U.S. RESEARCH ROUNDUP-Aramark, Mirati Therapeutics, UnitedHealth Group
Press Digest: Wall Street Journal - Oct. 9
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal (updated)
Brief: Bristol Myers Squibb Diversifies Oncology Portfolio With Acquisition Of Mirati Therapeutics
Bristol-Myers Squibb to acquire Mirati Therapeutics for $58 per share
U.S. STOCKS ON THE MOVE-Frontdoor, gold miners, UniFirst
U.S. STOCKS ON THE MOVE-ARS Pharma, AMC, Eli Lilly
BMO Capital Markets raises Mirati's PT on buyout potential
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Akili, Tesla
Amgen's cancer drug to remain in market despite negative vote - analysts
U.S. STOCKS ON THE MOVE-Tesla, Mirati Therapeutics, Exxon Mobil
Mirati Therapeutics falls on report of potential acquisition
Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News (updated)
Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News
Brief: Sanofi To Explore Acquisition Of Cancer Drugmaker Mirati - Bloomberg News
Brief: Ecor1 Capital Reports 8.5% Passive Stake In Mirati Therapeutics, Inc. As Of Sept. 22-SEC Filing
Brief: Mirati Therapeutics Announces Departure Of Chief Financial Officer Laurie Stelzer